Bupropion is the only major antidepressant that works primarily through dopamine and norepinephrine reuptake inhibition, with no meaningful effect on serotonin. This mechanistic distinction is clinically significant: it is the reason bupropion is associated with weight loss rather than gain, with activation rather than sedation, and with a near-absence of sexual side effects — all of which are serotonin-mediated phenomena.
The drug comes in three formulations: immediate-release (IR), sustained-release (SR dosed twice daily), and extended-release (XL, once daily). XL is the most commonly prescribed form and is typically preferred for adherence. Zyban is simply bupropion SR marketed under a different brand name for smoking cessation — the same molecule, a different indication.
The most important contraindication for bupropion is eating disorders. The drug significantly lowers the seizure threshold, and purging behaviors in bulimia create electrolyte abnormalities that greatly amplify that risk. It is absolutely contraindicated in patients with anorexia nervosa, bulimia nervosa, or a history of seizure disorder. Abrupt withdrawal from alcohol or benzodiazepines also sharply raises seizure risk and is another contraindication.
Best suited for: Depression characterized by low energy, fatigue, or hypersomnia; patients concerned about sexual dysfunction or weight gain; smokers who want to quit; patients without a history of eating disorders or seizures.